Roka Bioscience

The partners will develop a new product using MBio's multiplex, point-of-care testing system and Roka's experience in food safety testing.

At the end of the quarter, the company had 39 of its Atlas molecular testing instruments placed with customers under commercial agreements compared to 36 in Q3 2014.

The firm, which went public about a year ago, said that the offerings may consist of its common stock, preferred stock, warrants, senior or subordinated debt securities, and units.

While instrument placements in the quarter increased to 41 from 36 a year ago, the firm missed the consensus analysts' estimate on the top and bottom lines. 

The revenue gain was the result of an increase in the number of placements of its Atlas instruments with commercial customers.

The fourth quarter revenue growth resulted from an increase in its Atlas instrument placements, as well as an increase in the commercial use of the instrument. 

NEW YORK (GenomeWeb) – Roka Bioscience reported after the close of the market Thursday that its third quarter revenues nearly tripled year over year as it trimmed its net loss.

NEW YORK (GenomeWeb) – Roka Bioscience said in its Form 10-Q this week that it exercised an option to reduce the royalty rate it pays to Hologic.

NEW YORK (GenomeWeb) – Molecular diagnostics firm Roka Bioscience today reported that its second quarter revenues more than doubled year over year.

NEW YORK (GenomeWeb) – Roka Bioscience today priced its initial public offering of 5 million shares at $12 per share, raising gross proceeds of $60 million.

Pages

New results from the NASA Twins Study indicate that the immune system may rev up when in space, the Washington Post reports.

Kelvin Droegemeier, the new science advisor, spoke at the American Association for the Advancement of Science meeting, Geekwire reports.

In PNAS this week: whole-genome assembly for the white shark, paper-based microfluidic method for detecting the malaria parasite, and more.

The World Health Organization has announced the members of its gene-editing committee, according to NPR.